Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy
Gabriele Simontacchi(Azienda Ospedaliero-Universitaria Careggi), Umberto Ricardi(Azienda Ospedaliero Universitaria San Giovanni Battista), Michela Buglione(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Andrea Riccardo Filippi(University of Turin), Lorenzo Livi(European Society for Sexual Medicine), Francesco Merli(Azienda Sanitaria Unità Locale di Reggio Emilia), Barbara Botto(Palmetto Hematology Oncology), Stefano Maria Magrini(University of Brescia), Luca Vaggelli(Azienda Ospedaliero-Universitaria Careggi), Cinzia Iotti(Azienda Sanitaria Unità Locale di Reggio Emilia), Calogero Saieva(Istituto per lo Studio e la Prevenzione Oncologica), Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia)
International Journal of Radiation Oncology*Biology*Physics
April 17, 2015
Cited by 30
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646